Objective:

To explore how twin-screw extrusion and continuous manufacturing technologies are transforming drug development processes in biotechnology.

Key Findings:

• Twin-screw extruders maintain geometric similarity, ensuring consistent processing conditions across different scales.
• Real-time monitoring reduces batch-to-batch variability and waste, particularly with expensive APIs.
• Continuous manufacturing supports the development of fixed-dose combinations and precision medicine.
• Lab-scale units can process small quantities, making them suitable for early development and clinical trials.

Interpretation:

Continuous manufacturing technologies, particularly twin-screw extrusion, significantly enhance the scalability, precision, and efficiency of drug development, addressing the unique challenges faced by biotechs, especially in rare disease treatments.

Limitations:

• The article does not provide quantitative data on the performance improvements from using continuous manufacturing.
• Potential challenges in implementing these technologies in existing manufacturing setups are not discussed.

Conclusion:

Continuous manufacturing technologies are reshaping drug development by improving scalability, precision, and efficiency, which is crucial for biotechs working on complex and rare disease treatments.